Evommune presents EVO301 phase 2a data showing primary endpoint met in atopic dermatitis
EVMN•Evommune said EVO301 met its phase 2a primary endpoint in atopic dermatitis, with a 33% placebo-adjusted EASI improvement at week 12. The company reported approximately $290 million in cash and investments, with runway projected into the second half of 2029.
1. Phase 2a results
EVO301 met its primary endpoint in a phase 2a atopic dermatitis trial, delivering a 33% placebo-adjusted EASI improvement at week 12. Evommune reported no treatment-related serious or severe adverse events and no cases of conjunctivitis.
2. Upcoming trials and cash
Evommune plans to initiate a phase 2b atopic dermatitis trial in mid-2027 and is targeting the first half of 2027 to begin a phase 2a ulcerative colitis trial. Top-line data from its EVO756 phase 2b migraine trial are expected in the second half of 2027. The company reported approximately $290 million in cash and investments, providing a projected runway into the second half of 2029.
